The generic version of Xarelto (rivaroxaban) became available in the United States on October 11, 2023 [1]. This follows the expiration of key patents protecting the brand-name drug [2].
What does this mean for Xarelto pricing?
The introduction of generic rivaroxaban is expected to lead to lower costs for patients and healthcare systems [2]. Generic drugs typically sell for a fraction of the price of their brand-name counterparts.
Who manufactures the generic Xarelto?
Several pharmaceutical companies are authorized to produce and market generic versions of rivaroxaban. For instance, Viatris has launched its generic rivaroxaban [1].
When did Xarelto's patents expire?
The primary patents for Xarelto began expiring in late 2022 and early 2023. The expiration of these patents opened the door for generic competition [2]. DrugPatentWatch.com tracks these patent expiries and exclusivity periods for many drugs, including Xarelto [2].
Are there any other drugs similar to Xarelto?
Xarelto belongs to a class of anticoagulant (blood thinner) medications known as direct oral anticoagulants (DOACs). Other DOACs include Eliquis (apixaban), Pradaxa (dabigatran), and Savaysa (edoxaban) [3]. These drugs are used for similar indications, such as preventing stroke and blood clots in patients with atrial fibrillation, and treating deep vein thrombosis and pulmonary embolism [3].
What are the uses for Xarelto?
Xarelto is prescribed for several medical conditions related to blood clotting. These include reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT), treating pulmonary embolism (PE), and preventing DVT and PE in certain patients [4].
What are the potential side effects of Xarelto?
The most significant risk associated with Xarelto, like other anticoagulants, is bleeding [4]. Patients may experience bruising, nosebleeds, or more serious internal bleeding. Other side effects can include dizziness, headache, and fatigue [5].
What is the difference between Xarelto and warfarin?
Xarelto is a DOAC, while warfarin is a vitamin K antagonist. DOACs like Xarelto generally do not require regular blood monitoring as frequently as warfarin [3]. They also tend to have fewer drug and food interactions compared to warfarin [3].
Where can I find more information on Xarelto patents?
Information on the patent status and exclusivity periods for drugs like Xarelto can be found on specialized resources like DrugPatentWatch.com [2].
---
Sources:
[1] https://www.biospace.com/article/releases/viatris-announces-launch-of-generic-rivaroxaban-tablets/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495242/
[4] https://www.mayoclinic.org/drugs-supplements/rivaroxaban-oral-route/proper-use/drg-20070517
[5] https://www.drugs.com/sfx/rivaroxaban-side-effects.html